USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
FOX CHASE CHEMICAL DIVERSITY CENTER, INC
Address:
3805 OLD EASTON RD
DOYLESTOWN, PA 18902-
Phone:
N/A
URL:
N/A
EIN:
126365221
DUNS:
828761002
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $936,255.00 2
SBIR Phase II $1,919,724.00 1
STTR Phase I $600,000.00 2

Award List:

Pathogen-Specific Regulation of Protein Assembly

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$600,000.00
Agency:
HHS
Principal Investigator:
Allen B. Reitz
Abstract:
DESCRIPTION (provided by applicant): One sixth of the world's population has an infectious disease, and new agents involving novel mechanisms less likely to engender resistance are needed if for no other reason than the almost certain emergence of mutant s trains and new pathogens in the future.… More

Riluzole Prodrugs for Melanoma and ALS

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$336,255.00
Agency:
HHS
Principal Investigator:
Allen B. Reitz – 215-589-6435
Abstract:
DESCRIPTION (provided by applicant): Metastatic melanoma has few treatment options, and the current therapeutic standard of care is dacarbazine which is a highly cytotoxic drug with severe side effects including vomiting, headache and hair loss. Treatmentwith dacarbazine has a median… More

DC-SIGN Inhibitors for the Treatment of HIV Infection

Award Year / Program / Phase:
2013 / STTR / Phase I
Award Amount:
$300,000.00
Agency:
HHS
Principal Investigator:
Allen B. Reitz – 215-589-6435
Research Institution:
DREXEL UNIVERSITY
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): DC-SIGN (dendritic cell specific ICAM-3-grabbing non-integrin), a membrane protein of C-type lectin family, is found in high levels on monocyte-derived DCs, some macrophages, and activated B cells. In vivo, DC-SIGN- positive cells were demonstrated in lymph… More

New therapeutics for the treatment of Acinetobactor baumannii infections.

Award Year / Program / Phase:
2013 / STTR / Phase I
Award Amount:
$300,000.00
Agency:
HHS
Principal Investigator:
Allen B. Reitz – 215-589-6435
Research Institution:
UNIVERSITY OF PENNSYLVANIA
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Acinetobacter are strictly aerobic, non-fermentative Gram-negative bacilli that are of major concern in human health, in particular the species Acinetobacter baumannii. They are responsible for clinically important infections that cause a wide variety of maladies… More

Riluzole Prodrugs for Melanoma and ALS

Award Year / Program / Phase:
2013 / SBIR / Phase II
Award Amount:
$1,919,724.00
Agency:
HHS
Principal Investigator:
Allen B. Reitz – 215-589-6435
Abstract:
DESCRIPTION (provided by applicant): We have identified a novel Type IIb prodrug of riluzole, FC-311, which has the potential to revolutionize therapy for the treatment of the devastating condition of metastatic melanoma acting via a novel glutamatergic mechanism of action, and also be useful to… More